The reason for this is that IL1β is believed to exert its anti-tumour effects in the bone by inhibiting the expansion of the metastatic niche, bone resorption and the vicious cycle of bone metastasis, whereas IL1β promotes lung metastasis via reducing anti-tumour immune response [2,3,7,10,13]. The gene discussed is IL1B; the disease is neoplasm.